France· FR:61015604
ANZUPGO 20 mg/g, crème
A delgocitinib product containing delgocitinib, registered in France by LEO PHARMA A/S (DANEMARK), on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Delgocitinib is registered in 15 of 19 countries.
Countries holding a registration under ATC D11AH11 (delgocitinib), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 10 of them publish a price we can compare per daily dose
Delgocitinib · ATC D11AH11
15 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- DELGOCITINIB
- Manufacturer
- LEO PHARMA A/S (DANEMARK)
- Country
- France (FR)
- ATC code
- D11AH11
- ATC class
- Delgocitinib
- Defined daily dose
- 40 mg, T
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip1334009303030921 tube(s) laminé polyéthylène basse densité (PEBD) de 60 gEUR 547.82
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Delgocitinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaANZUPGOLEO Pharma A/S, Ballerup
- NorwayAnzupgoLEO
- United StatesAnzupgoLEO Pharma, Inc
- IrelandAnzupgo 20 mg/g creamLEO Pharma A/S
- SwitzerlandAnzupgo
- NetherlandsAnzupgo 20 mg/g crèmeLeo Pharma A/S
- PolandAnzupgoLEO Pharma A/S
- SwedenAnzupgo 20 mg/g KrämLEO Pharma A/S
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Anzupgo
- Iceland · Anzupgo
- Liechtenstein · Anzupgo
- Norway · Anzupgo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9d9e3c31-0377-437a-9880-daa804abfca5 GET /v1/drugs/9d9e3c31-0377-437a-9880-daa804abfca5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "61015604",
"date_amm": "2024-09-19",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/24/1851",
"substance": "DELGOCITINIB",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "crème",
"voies_administration": "cutanée",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about delgocitinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.